close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc
Search

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

41.67 -0.45

Tugev "osta" hinnang

Hinna uuendus 29. jaan 2026, 20:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

40.92

Max

41.87

Põhinäitajad

By Trading Economics

Sissetulek

-6.2M

-91M

Kasumimarginaal

-867.293

Töötajad

316

EBITDA

4M

-90M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+27.6% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

31M

3.3B

Eelmine avamishind

42.12

Eelmine sulgemishind

41.67

Uudiste sentiment

By Acuity

50%

50%

151 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. jaan 2026, 22:31 UTC

Tulu

KLA Posts Higher 2Q Profit On Product and Services Sales Growth

DJ

Loe

29. jaan 2026, 22:05 UTC

Tulu

Stryker Logs Higher 4Q Profit On Sales Gains

DJ

Loe

29. jaan 2026, 21:54 UTC

Tulu

Visa 1Q Sales Climb on Strong Holiday Shopping -- Update

DJ

Loe

29. jaan 2026, 21:36 UTC

Tulu

Visa 1Q Sales Climb on Strong Holiday Shopping

DJ

Loe

29. jaan 2026, 23:57 UTC

Omandamised, ülevõtmised, äriostud

Aluminum Corp. of China: to Hold 67% of Joint Venture With Rio Tinto

DJ

Loe

29. jaan 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Aluminum Corp. of China: Deal Valued at Roughly BRL4.69 Billion

DJ

Loe

29. jaan 2026, 23:53 UTC

Omandamised, ülevõtmised, äriostud

Aluminum Corp. of China Says It, Rio Tinto Propose to Buy 69% Stake in Companhia Brasileira de Aluminio S.A.

DJ

Loe

29. jaan 2026, 23:51 UTC

Tulu

Correction to Intel Earnings Article on Jan. 22 -- WSJ

DJ

Loe

29. jaan 2026, 23:49 UTC

Market Talk

Nikkei May Decline After Wall Street Tech Selloffs -- Market Talk

DJ

Loe

29. jaan 2026, 23:49 UTC

Market Talk

Gold Rises Amid Ongoing Iran Tensions -- Market Talk

DJ

Loe

29. jaan 2026, 23:47 UTC

Market Talk

Pro Medicus Looks Attractive Ahead of 1H Result -- Market Talk

DJ

Loe

29. jaan 2026, 23:35 UTC

Tulu

Apple Posts Blowout iPhone Sales on Surging China Demand -- 2nd Update

DJ

Loe

29. jaan 2026, 23:32 UTC

Market Talk

REA's 1H Result Could Jolt Share Price More Than Usual -- Market Talk

DJ

Loe

29. jaan 2026, 23:32 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

29. jaan 2026, 23:15 UTC

Market Talk
Tulu

Visa Says High Earners Still Lead Spending Growth -- Market Talk

DJ

Loe

29. jaan 2026, 22:27 UTC

Tulu

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

DJ

Loe

29. jaan 2026, 22:27 UTC

Tulu

GE Vernova Gains After Earnings. Guidance Boost Was Enough to Lift the Stock. -- Barrons.com

DJ

Loe

29. jaan 2026, 22:12 UTC

Tulu

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

DJ

Loe

29. jaan 2026, 21:55 UTC

Tulu

Micron Stock Rises. Samsung Signals a 'Golden Era' for Memory Chips. -- Barrons.com

DJ

Loe

29. jaan 2026, 21:50 UTC

Market Talk
Tulu

Financial Services Roundup: Market Talk

DJ

Loe

29. jaan 2026, 21:50 UTC

Tulu

These Stocks Are Today's Movers: Microsoft, Meta, Tesla, Joby Aviation, SAP, Royal Caribbean, and More -- Barrons.com

DJ

Loe

29. jaan 2026, 21:50 UTC

Market Talk
Tulu

Health Care Roundup: Market Talk

DJ

Loe

29. jaan 2026, 21:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

DJ

Loe

29. jaan 2026, 21:49 UTC

Tulu

Honeywell Delivers Solid Earnings Ahead of Its Corporate Breakup -- Barrons.com

DJ

Loe

29. jaan 2026, 21:46 UTC

Tulu

Apple Posts Blowout iPhone Sales on Surging China Demand -- Update

DJ

Loe

29. jaan 2026, 21:36 UTC

Tulu

Lockheed Martin Stock Jumps on Guidance and Government Missile Deal -- Barrons.com

DJ

Loe

29. jaan 2026, 21:32 UTC

Tulu

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

DJ

Loe

29. jaan 2026, 21:32 UTC

Tulu

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

DJ

Loe

29. jaan 2026, 21:30 UTC

Tulu

Apple Posts Blowout IPhone Sales on Surging China Demand -- WSJ

DJ

Loe

29. jaan 2026, 21:30 UTC

Tulu

Apple 1Q Mac Rev $8.39B >AAPL

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

27.6% tõus

12 kuu keskmine prognoos

Keskmine 54.09 USD  27.6%

Kõrge 62 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

14

Osta

0

Hoia

0

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Bullish Evidence

Recent bullish events outweigh bearish events.

Pikk perspektiiv

Neutral Evidence

The bullish and bearish events are balanced.

Sentiment

By Acuity

151 / 352 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Muud aktsiad sektorist

JNJ

Johnson and Johnson

227.3

↓-0.24%

ISRG

Intuitive Surgical Inc

507.91

↓-2.78%

ABT

Abbott Laboratories

106.03

↑ +0.05%

MDT

Medtronic PLC

100.97

↑ +0.31%

A

Agilent Technologies Inc

133.13

↓-0.58%
help-icon Live chat